Edition:
United Kingdom

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

103.38USD
20 Aug 2018
Change (% chg)

-- (--)
Prev Close
$103.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
227,857
52-wk High
$121.91
52-wk Low
$51.11

Latest Key Developments (Source: Significant Developments)

Intercept Sees Ocaliva Net Sales To Fall In Quarter Ended March 31
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Intercept Pharmaceuticals Inc ::EXPECTS NET SALES OF OCALIVA FOR QUARTER ENDED MARCH 31, TO BE SLIGHTLY LOWER THAN NET SALES OF OCALIVA FOR QUARTER ENDED DEC 31, 2017​.  Full Article

Intercept Pharma Says U.S. Court Granted Defendants Motion & Dismissed With Prejudice Derivative Lawsuit Purportedly Brought On Behalf Of Company
Monday, 26 Mar 2018 

March 26 (Reuters) - Intercept Pharmaceuticals Inc ::INTERCEPT PHARMA - U.S. COURT GRANTED DEFENDANTS MOTION & DISMISSED WITH PREJUDICE DERIVATIVE LAWSUIT PURPORTEDLY BROUGHT ON BEHALF OF COMPANY.INTERCEPT PHARMA SAYS LAWSUIT WAS FILED BY A STOCKHOLDER OF CO ON AUG 4, 2017 - SEC FILING.  Full Article

Intercept Pharma Says Shifting Guidance For Announcement Of Phase 3 Reverse Trial In Nash Patients With Compensated Cirrhosis To Q1 2018
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Intercept Pharmaceuticals Inc ::INTERCEPT PHARMA SAYS SHIFTING GUIDANCE FOR ANNOUNCEMENT OF PHASE 3 REVERSE TRIAL IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS TO Q1 2018 - SEC FILING.  Full Article

Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Intercept Pharmaceuticals Inc :Intercept Pharmaceuticals reports third quarter 2017 financial results and provides business update.Intercept - ‍non-GAAP adjusted operating expenses for fiscal year ending Dec 31, 2017 will fall in middle of range of $380 million to $420 million​.Intercept Pharmaceuticals - ‍interim analysis in flagship Phase 3 regenerate trial on track to report in H1 2019.Intercept Pharmaceuticals Inc- to streamline operating expenses, decided to deprioritize interest-767 development program for foreseeable future​.Intercept Pharmaceuticals Inc - qtrly ‍rev $41.3 million versus $5.2 million​.Q3 earnings per share view $-3.38, revenue view $37.0 million -- Thomson Reuters I/B/E/S.Intercept Pharmaceuticals inc qtrly net loss per common and potential common share basic and diluted $2.89‍​.  Full Article

Intercept Pharma posts positive results from Phase 2 AESOP trial
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Intercept Pharmaceuticals Inc :Intercept announces positive results from Phase 2 AESOP trial evaluating OCA for the treatment of patients with primary sclerosing cholangitis at The Liver Meeting 2017.Intercept Pharmaceuticals Inc - ‍OCA met primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeks​.  Full Article

Intercept extends strategic partnership with Target PharmaSolutions for Target-Nash
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Intercept Pharmaceuticals Inc :Intercept (ICPT) extends strategic partnership with Target PharmaSolutions for Target-Nash.Target PharmaSolutions - Intercept has extended its strategic partnership for Target-Nash to a multi-year agreement​.  Full Article

Intercept Pharmaceuticals Q3 sales $4.7 million
Thursday, 3 Nov 2016 

Intercept Pharmaceuticals Inc : Intercept pharmaceuticals inc- eu marketing approval decision for ocaliva anticipated by year end 2016 . Intercept pharmaceuticals inc- eu launch of ocaliva anticipated in early 2017 . Intercept pharmaceuticals reports third quarter 2016 financial results and provides business update .Q3 sales $4.7 million versus i/b/e/s view $4.8 million.  Full Article

EMA recommends conditional approval of Abbvie leukemia drug
Friday, 14 Oct 2016 

European Medicines Agency(EMA): EU Medicines Agency recommendations for October 2016 . EU Medicines Agency recommends approval of Abbvie Inc’S Venetoclax/Venclexta to treat leukaemia . EU Medicines Agency recommends conditional marketing approval of Intercept Pharmaceuticals Inc’S Ocaliva to treat primary biliary cirrhosis Link to source: (http://bit.ly/2dYKT7R) (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 Mln-$185 Mln

* INTERCEPT PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS, ISSUES 2018 OCALIVA NET SALES GUIDANCE AND PROVIDES BUSINESS UPDATE